Updates on CAR T-Cell Therapy in Myeloma: Is the Future Bright?

Published on

Topics include: Treatments

The emergence of the impressive, high-tech CAR T-cell therapy, using your own genetically modified T cells to combat cancer, has generated a lot of buzz throughout the cancer community. Although it is still being evaluated in clinical trials for certain types of cancers, many multiple myeloma patients wonder if it could work for them. Where is research today on CAR T-cell therapy for myeloma? What role will this immunotherapy play in myeloma care? On location at the 2018 American Society of Clinical Oncology (ASCO) meeting in Chicago, Dr. James Berenson gives an expert perspective on the efficacy, value, toxicity and cost of CAR T-cell therapy for myeloma. Watch now to find out the latest treatment developments.

View more programs featuring and

Transcript

There are a number of ways it's being done.  A lot of people are targeting BCMA.  Others are targeting other protein, and, you know, there's a lot of work to be done on this in order to make it user friendly.  Right now it's pretty cumbersome.  It's really being done at major medical centers only, and there's certainly some side effects, something called cytokine release syndrome, which can be really daunting for these health staff, the nurses and ancillary healthcare professionals to take care of.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

BCMA Biomarker Update: What Can One Drop of Blood Reveal About Your Myeloma?

What can one drop of blood reveal about your myeloma? Patient Power Founder, Andrew Schorr, is joined by myeloma expert Dr. James Berenson at ASCO 2018 to discuss the latest developments in biomarkers to evaluate change in clinical status.

Published:

Can Myeloproliferative Neoplasm Drugs Help Myeloma Patients?

Have researchers unlocked the potential of a commonly used MPN therapy to treat myeloma? Find out the latest treatment news announced at ASCO 2018 from myeloma expert Dr. James Berenson.

Published:

ASCO 2018: Updates on the ARROW Study for Myeloma

Can a change in frequency influence the efficacy of a treatment? Dedicated researcher Dr. James Berenson shares results announced at ASCO 2018 from the ARROW study with a once-weekly regimen. How did patients tolerate it? Watch now to find out.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on March 28, 2019